Rituximab vs placebo
Any adverse event · patients with IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
It is very uncertain whether rituximab changes any adverse event compared with placebo (very low certainty).
1 finding from 1 review
- Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies 2016 · Cochrane Headline outcomes onlyRR 1.18 [0.84, 1.66]2 studies · 80 participantsVery low